AstraZeneca boosts King’s Cross with HQ expansion
AstraZeneca has given King’s Cross a shot in the arm today (21 February), opening fresh floors at its UK headquarters at 2 Pancras Square and more than doubling its office space at the site.
The pharmaceutical firm has taken another 22,000 sq ft at the Argent-developed office building, in addition to the 15,000 sq ft it has occupied since 2019.
The space will house workers previously located in Luton, consolidating the drug maker’s presence in central London. Employees at the site work across the medical, marketing, digital, communications, finance and HR functions, supporting scientists working elsewhere in AstraZeneca’s biopharmaceutical and oncology teams.
AstraZeneca has given King’s Cross a shot in the arm today (21 February), opening fresh floors at its UK headquarters at 2 Pancras Square and more than doubling its office space at the site.
The pharmaceutical firm has taken another 22,000 sq ft at the Argent-developed office building, in addition to the 15,000 sq ft it has occupied since 2019.
The space will house workers previously located in Luton, consolidating the drug maker’s presence in central London. Employees at the site work across the medical, marketing, digital, communications, finance and HR functions, supporting scientists working elsewhere in AstraZeneca’s biopharmaceutical and oncology teams.
The company now lets more than a quarter of the 130,000 sq ft office building, which was designed by Allies and Morrison as part of the King’s Cross estate. Astra’s new fit-out by Ekho Studio is designed to “encourage office-based working,” it said in a statement.
Tom Keith-Roach, president of AstraZeneca UK, said: “Our move to Pancras Square puts us at the heart of London’s Knowledge Quarter, and brings us closer to partners, researchers, innovators and decision makers across the life sciences and healthcare system.
“This is a very exciting time at AstraZeneca UK. We’re looking forward to getting fully engaged and collaborating across the ecosystem to advance the UK as a life sciences powerhouse and improve societal good health.”
To send feedback, e-mail alex.daniel@eg.co.uk or tweet @alexmdaniel or @EGPropertyNews
